Expert Review of Anti-infective Therapy最新文献_第4页

Use of adjuvants to improve antibiotic efficacy and reduce the burden of antimicrobial resistance. 使用佐剂提高抗生素疗效，减轻抗菌素耐药性负担。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-01-01 Epub Date: 2024-12-27 DOI: 10.1080/14787210.2024.2441891

Teresa Gil-Gil, Pablo Laborda, José Luis Martínez, Sara Hernando-Amado

{"title":"Use of adjuvants to improve antibiotic efficacy and reduce the burden of antimicrobial resistance.","authors":"Teresa Gil-Gil, Pablo Laborda, José Luis Martínez, Sara Hernando-Amado","doi":"10.1080/14787210.2024.2441891","DOIUrl":"10.1080/14787210.2024.2441891","url":null,"abstract":"Introduction: The increase in antibiotic resistance, together with the absence of novel antibiotics, makes mandatory the introduction of novel strategies to optimize the use of existing antibiotics. Among these strategies, the use of molecules that increase their activity looks promising.Areas covered: Different categories of adjuvants have been reviewed. Anti-resistance adjuvants increase the activity of antibiotics by inhibiting antibiotic resistance determinants. Anti-virulence approaches focus on the infection process itself; reducing virulence in combination with an antibiotic can improve therapeutic efficacy. Combination of phages with antibiotics can also be useful, since they present different mechanisms of action and targets. Finally, combining antibiotics with adjuvants in the same molecule may serve to improve antibiotics' efficacy and to overcome potential problems of differential pharmacokinetics/pharmacodynamics.Expert opinion: The successful combination of inhibitors of β-lactamases with β-lactams has shown that adjuvants can improve the efficacy of current antibiotics. In this sense, novel anti-resistance adjuvants able to inhibit efflux pumps are still needed, as well as anti-virulence compounds that improve the efficacy of antibiotics by interfering with the infection process. Although adjuvants may present different pharmacodynamics/pharmacokinetics than antibiotics, conjugates containing both compounds can solve this problem. Finally, already approved drugs can be a promising source of antibiotic adjuvants.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"31-47"},"PeriodicalIF":4.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Update on actinomycetoma treatment: linezolid in the treatment of actinomycetomas due to Nocardia spp and Actinomadura madurae resistant to conventional treatments. 放线菌瘤治疗的最新进展：利奈唑胺用于治疗诺卡菌和硬膜放线菌引起的放线菌瘤，这些放线菌瘤对常规治疗具有耐药性。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-01-01 Epub Date: 2025-01-06 DOI: 10.1080/14787210.2024.2448723

Alexandro Bonifaz, Roxana S García-Sotelo, Fabiola Lumbán-Ramirez, Denisse Vázquez-González, José Iván Inclán-Reyes, Mario Eduardo Sierra-Garduño, Javier Araiza, David Chandler

{"title":"Update on actinomycetoma treatment: linezolid in the treatment of actinomycetomas due to Nocardia spp and Actinomadura madurae resistant to conventional treatments.","authors":"Alexandro Bonifaz, Roxana S García-Sotelo, Fabiola Lumbán-Ramirez, Denisse Vázquez-González, José Iván Inclán-Reyes, Mario Eduardo Sierra-Garduño, Javier Araiza, David Chandler","doi":"10.1080/14787210.2024.2448723","DOIUrl":"10.1080/14787210.2024.2448723","url":null,"abstract":"Introduction: Mycetoma is a chronic granulomatous infection, common throughout tropical regions, and is considered a neglected disease that mostly affects impoverished populations. Mycetoma is divided into eumycetoma, caused by fungi, and actinomycetoma, caused by filamentous bacteria. Clinical presentation is distinctive, and making the diagnosis is usually not difficult; however, access to safe and effective treatments is a major challenge. There is not a single best treatment, with the choice of treatment depending on etiology, severity and extent of disease, and patient comorbidities.Areas covered: The following topics regarding actinomycetoma are discussed. I) Background information on actinomycetoma, and etiology. II) Differences between actinomycetoma caused by Nocardia, and cutaneous nocardiosis. III) Review of the treatment options for actinomycetoma, caused by three species - Nocardia, Actinomadura, and Streptomyces. IV) Experience using linezolid in the treatment of mycetoma caused by Nocardia spp. and Actinomadura madurae.Expert opinion: Multiple treatment regimens for actinomycetoma were discussed according to the causative agent. Experience in using linezolid in combined therapy for actinomycetoma caused by Nocardia in which conventional treatment options failed was also presented. The first case report of treatment with linezolid for mycetoma caused by Actinomadura madurae is presented in this article.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"79-89"},"PeriodicalIF":4.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Could the next disease X be pandemic of virus-induced encephalitis? what should be our first medical response? 下一个 "X 病 "会是由病毒引起的脑炎大流行吗？我们的第一医疗反应应该是什么？

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-01-01 Epub Date: 2025-01-03 DOI: 10.1080/14787210.2024.2432277

Mina T Kelleni

引用次数: 0

Optic and peripheral neuropathy associated with short and prolonged administration of tedizolid: a review. 视神经和周围神经病变与短期和长期施用泰德唑胺有关：综述。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-01-01 Epub Date: 2025-01-07 DOI: 10.1080/14787210.2024.2448143

Angeliki Katsarou, Maria Tzikopoulou, Dimitrios Papadopoulos, Sotiria Palioura, Matthew E Falagas

{"title":"Optic and peripheral neuropathy associated with short and prolonged administration of tedizolid: a review.","authors":"Angeliki Katsarou, Maria Tzikopoulou, Dimitrios Papadopoulos, Sotiria Palioura, Matthew E Falagas","doi":"10.1080/14787210.2024.2448143","DOIUrl":"10.1080/14787210.2024.2448143","url":null,"abstract":"Introduction: Tedizolid is a novel antibiotic of the class of oxazolidinones. This review evaluates the published literature on the optic and peripheral neuropathy associated with short and prolonged administration of tedizolid.Areas covered: A review of published data from 4 databases was conducted, regarding the development of optic and peripheral neuropathy in patients who received tedizolid for short or prolonged duration. A total of 1,212 records were screened; 33 were included in this review. No peripheral or optic neuropathy cases were reported in 6 randomized controlled trials that studied tedizolid use for a short course. In contrast, 2 cases with optic neuropathy (1 not supported by objective findings) in 87 patients of the prospective studies were identified. Additionally, in a total of 277 patients who participated in the 6 retrospective studies, 9 adverse events related to optic or peripheral neuropathy and 1 case with foot drop in 22 patients of the relevant cases reports were recorded.Expert opinion: The available data suggests that the safety profile of tedizolid is favorable, especially when given for a short time. However, more clinical studies are needed regarding its long-term use, given that the neurotoxicity induced by oxazolidinones may be time and dose-dependent.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"49-65"},"PeriodicalIF":4.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The evolving scenario of HCV-related mixed cryoglobulinemia and B-cell lymphoma in the era of direct-acting antivirals. 在直接作用抗病毒药物时代，hcv相关的混合冷球蛋白血症和b细胞淋巴瘤的演变情况。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-01-01 Epub Date: 2025-01-03 DOI: 10.1080/14787210.2024.2442475

Antonio Tonutti, Davide Polverini, Stella De Nicola, Angela Ceribelli, Matteo Soleri, Maria De Santis, Alessio Aghemo, Carlo Selmi, Nicola Pugliese

{"title":"The evolving scenario of HCV-related mixed cryoglobulinemia and B-cell lymphoma in the era of direct-acting antivirals.","authors":"Antonio Tonutti, Davide Polverini, Stella De Nicola, Angela Ceribelli, Matteo Soleri, Maria De Santis, Alessio Aghemo, Carlo Selmi, Nicola Pugliese","doi":"10.1080/14787210.2024.2442475","DOIUrl":"10.1080/14787210.2024.2442475","url":null,"abstract":"Introduction: Hepatitis C virus (HCV) infection represents a significant global health burden, particularly due to its extrahepatic immune-mediated manifestations, such as mixed cryoglobulinemia, associated vasculitis (CryoVas), and non-Hodgkin B-cell lymphoma (B-NHL), which pose significant challenges. The advent of direct-acting antiviral (DAA) has changed the therapeutic landscape for HCV-related complications.Areas covered: This review explores the evolving epidemiology and management of HCV extrahepatic manifestation and lymphoproliferative disorders in the era of DAAs. It examines the efficacy of DAAs in controlling CryoVas and their complex role in HCV-related B-cell lymphoma. The literature search included studies on the immunological dynamics between HCV, CryoVas, and lymphoma, focusing on the impact of sustained virological response (SVR) on immune dysregulation, relapse risk, refractory disease, and patient stratification based on risk profiles.Expert opinion: DAAs have significantly improved the management of HCV-related CryoVas and autoimmune manifestations, but remain a challenge in refractory cases and the risk of lymphoma. Future strategies should focus on refining risk stratification and integrating new therapeutic approaches to better address immune dysregulation and associated complications.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"19-30"},"PeriodicalIF":4.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New and emerging roles for inhalational and direct antifungal drug delivery approaches for treatment of invasive fungal infections. 吸入式和直接抗真菌给药方法在治疗侵袭性真菌感染方面的新作用。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-12-01 Epub Date: 2024-09-29 DOI: 10.1080/14787210.2024.2409408

Chin Fen Neoh, Wirawan Jeong, David C M Kong, Justin Beardsley, Philip Chi Lip Kwok, Monica A Slavin, Sharon C-A Chen

{"title":"New and emerging roles for inhalational and direct antifungal drug delivery approaches for treatment of invasive fungal infections.","authors":"Chin Fen Neoh, Wirawan Jeong, David C M Kong, Justin Beardsley, Philip Chi Lip Kwok, Monica A Slavin, Sharon C-A Chen","doi":"10.1080/14787210.2024.2409408","DOIUrl":"10.1080/14787210.2024.2409408","url":null,"abstract":"Introduction: The rising prevalence of difficult-to-treat, deep-seated invasive fungal diseases (IFD) has led to high mortality. Currently available antifungal treatments, administered predominantly orally or intravenously, may not sufficiently penetrate certain body sites, and/or are associated with systemic toxicity. Little is known about how to position alternative administration approaches such as inhalational and direct drug delivery routes.Areas covered: This review provides an updated overview of unconventional drug delivery strategies for managing IFD, focusing on inhalational (to target the lungs) and direct delivery methods to the central nervous system, bone/joint, and eyes. Novel compounds (e.g. opelconazole) and existing antifungals with innovative drug delivery systems currently undergoing clinical trials and/or used off-label in the clinical setting are discussed.Expert opinion: For both inhalational agents and direct delivery approaches, there are similar challenges that include the absence of: approved formulations for specific administration routes, delivery vehicles that are simple and safe to use whilst maintaining potency and efficiency of delivery, animal models suitable for investigating pharmacokinetic/pharmacodynamic profiles of inhaled antifungals, and consensus on the composite endpoints and intervals for of follow-up in clinical trials. To meet these challenges, cooperation of all stakeholders in drug development and regulation is required.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1085-1098"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Now that griseofulvin is not available, what to do with tinea capitis treatments? 现在没有了格列齐芬，该如何治疗头癣呢？

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-12-01 Epub Date: 2024-09-19 DOI: 10.1080/14787210.2024.2405936

Alexandro Bonifaz, Paola Lumbán-Ramírez, Roxana S García-Sotelo, Helena Vidaurri de la Cruz, Mirna Toledo-Bahena, Adriana Valencia-Herrera

{"title":"Now that griseofulvin is not available, what to do with tinea capitis treatments?","authors":"Alexandro Bonifaz, Paola Lumbán-Ramírez, Roxana S García-Sotelo, Helena Vidaurri de la Cruz, Mirna Toledo-Bahena, Adriana Valencia-Herrera","doi":"10.1080/14787210.2024.2405936","DOIUrl":"10.1080/14787210.2024.2405936","url":null,"abstract":"Introduction: Griseofulvin, discovered in 1939 and commercially available since 1959, was the first oral antifungal agent effective against dermatophytosis, particularly tinea capitis. Although it was eventually superseded by azole antifungals due to its long treatment duration and reliance on keratopoiesis, griseofulvin remains notable for its effectiveness and safety in treating tinea capitis, especially when caused by Microsporum canis. However, due to a decline in cases and commercial unavailability, alternative treatments are now required.Areas covered: The following topics regarding to other treatments were discussed: (I) The efficacy of alternative antifungal agents such as terbinafine, itraconazole, and fluconazole, in the treatment of tinea capitis. (II) The use and role of topical therapies. (III) Experience in the management of tinea capitis.Expert opinion: The usefulness of oral terbinafine as a replacement for griseofulvin in the treatment of tinea capitis and why it is the preferred drug in elderly patients was discussed. Challenges with Microsporum spp. and the use of fluconazole in pediatric patients were also analyzed. Support for the use of topical treatment as an adjunctive treatment for tinea capitis was highlighted.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1017-1022"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 更正。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-12-01 Epub Date: 2020-10-15 DOI: 10.1080/14787210.2020.1836819

引用次数: 0

Ceftolozane/Tazobactam treatment for patients with hospital-acquired and ventilatory-associated bacterial pneumonia in Canada in 2022-2024: results from the CLEAR registry. 2022-2024 年加拿大医院获得性和呼吸机相关细菌性肺炎患者的头孢唑烷/他唑巴坦治疗：CLEAR 登记结果。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-12-01 Epub Date: 2024-09-26 DOI: 10.1080/14787210.2024.2405930

George G Zhanel, Rita Dhami, Melanie Baxter, Maggie Wong, Yazdan Mirzanejad, Justin Kosar, Carlos Cervera, Neal Irfan, Sergio Borgia, Alex Serebryanskyy, Robert Ariano, Michel Savoie, Carlo Tascini, Andrew Walkty, James A Karlowsky

{"title":"Ceftolozane/Tazobactam treatment for patients with hospital-acquired and ventilatory-associated bacterial pneumonia in Canada in 2022-2024: results from the CLEAR registry.","authors":"George G Zhanel, Rita Dhami, Melanie Baxter, Maggie Wong, Yazdan Mirzanejad, Justin Kosar, Carlos Cervera, Neal Irfan, Sergio Borgia, Alex Serebryanskyy, Robert Ariano, Michel Savoie, Carlo Tascini, Andrew Walkty, James A Karlowsky","doi":"10.1080/14787210.2024.2405930","DOIUrl":"10.1080/14787210.2024.2405930","url":null,"abstract":"Background: We report results from the national CLEAR (Canadian Leadership on Antimicrobial Real-Life Usage) registry on the usage of ceftolozane/tazobactam in Canada from 2022 to 2024.Research design and methods: The authors reviewed the final data using the national ethics approved CLEAR study. Thereafter, the literature is surveyed regarding the usage of ceftolozane/tazobactam to treat patients with HABP and VABP via PubMed (up to May 2024).Results: Ceftolozane/tazobactam was primarily used as directed therapy to treat HABP and VABP caused by Pseudomonas aeruginosa. It was primarily used alone, or in combination with another agent, to treat resistant and multidrug-resistant (MDR) P. aeruginosa infections. Despite primarily being used to treat severely ill patients in intensive care units, its use was associated with relatively high microbiological/clinical cure rates, along with an excellent safety profile. Several reports attest to the microbiological/clinical efficacy and safety of using ceftolozane/tazobactam to treat HABP and VABP.Conclusions: In Canada, ceftolozane/tazobactam is primarily used as directed therapy alone, or in combination, to treat MDR P. aeruginosa infections. Though mostly used to treat severely ill patients in the ICU, ceftolozane/tazobactam use in HABP and VABP is associated with relatively high microbiological/clinical cure rates and an excellent safety profile.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1221-1228"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Continuous care engagement in clinical practice: perspectives on selected current strategies for people with HIV in the United States. 临床实践中的持续护理参与：美国针对艾滋病毒感染者的部分现行策略观点。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-12-01 Epub Date: 2024-10-17 DOI: 10.1080/14787210.2024.2412988

Merceditas S Villanueva, Darrell P Wheeler, Shauna Applin, Theo W Hodge, Barry Zack, Peter F Rebeiro

{"title":"Continuous care engagement in clinical practice: perspectives on selected current strategies for people with HIV in the United States.","authors":"Merceditas S Villanueva, Darrell P Wheeler, Shauna Applin, Theo W Hodge, Barry Zack, Peter F Rebeiro","doi":"10.1080/14787210.2024.2412988","DOIUrl":"10.1080/14787210.2024.2412988","url":null,"abstract":"Introduction: Modern antiretroviral therapy is associated with reduced rates of HIV-related morbidity and mortality. HIV viral suppression and retention in care are critically important outcomes requiring successful continuous patient engagement. However, barriers to such engagement are complex and require innovative solutions.Areas covered: A multistakeholder group of experts comprising clinicians and service delivery researchers assembled to clarify what constitutes engagement in HIV care and identify overarching themes that inform strategies in this field. This article captures this expert opinion and adds relevant literature on selected current best practices.Expert opinion: The multistakeholder group felt strongly that a better understanding of the facilitators of continuous care engagement was critical. Unlike 'retention in care,' 'engagement in care' for an individual is nuanced, flexible, evolves and requires ongoing communication between patients, providers, and other key stakeholders. The following approaches highlight care engagement strategies at different stakeholder levels: 1) patient-level: personalized care and incentivization; 2) clinic-level: wraparound, co-localized, patient-centered low-barrier care, a diverse multidisciplinary team, patient support networks, and expanded use of telemedicine; 3) healthcare system-level: utilization of external partnerships. We propose a series of diverse and complementary approaches based on a more nuanced understanding of the qualitative aspects of engagement in care.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1043-1053"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0